Dose-dependent severe cutaneous reactions to imatinib

Dose-dependent severe cutaneous reactions to imatinib

The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutan...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer Vol. 88; no. 8; pp. 1157 - 1159
Main Authors: UGUREL, S, HILDENBRAND, R, DIPPER, E, HOCHHAUS, A, SCHADENDORF, D
Format: Journal Article
Language:English
Published: Basingstoke Nature Publishing Group 22-04-2003
Subjects:
Adult
Aged
Antineoplastic Agents - toxicity
Benzamides
Biological and medical sciences
Clinical
Drug Hypersensitivity - pathology
Drug toxicity and drugs side effects treatment
Female
Humans
Imatinib Mesylate
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Piperazines - toxicity
Pyrimidines - toxicity
Skin Diseases - chemically induced
Skin Diseases - pathology
Toxicity: skin, dermoskeleton
Antineoplastic agent
Human
Skin disease
Imatinib
Enzyme
Toxicity
c-kit
Transferases
Exanthema
Melanoma
Enzyme inhibitor
Malignant tumor
mast cells
Dose activity relation
Chemotherapy
Treatment
adverse drug reaction
Complication
Advanced stage
High dose
Protein-tyrosine kinase
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6600893